AI-enabled platform for automating cancer trial candidate identification
Economics of Care
Fund
Fund I
entry
2018
exit
2022
ACQUIRED BY
Tamarind Hill Team

About

Deep Lens

Deep Lens automates the identification of candidates for cancer trials through its AI-enabled digital pathology workflow platform. By corresponding lab and patient data, the Deep Lens platform, VIPER, speeds trial completion and makes connections to the “right trial for the right patient at the right time”.

Meet the

Deep Lens

team

Dave Billiter

Co-founder and CEO

TJ Bowen

Co-founder and COO

Simon Arkell

Co-founder and President

Join

Deep Lens

Interested in joining the team? Check out open positions across our portfolio here.

 Deep Lens Acquired by Paradigm
Portfolio
5
min read

Deep Lens Acquired by Paradigm

We are excited to announce the acquisition of Fund I portfolio company Deep Lens by Paradigm.

Explore other portfolio companies that we proudly partner with

Your partners on the path to B2B Healthcare Innovation.